Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized‐controlled trial

Aa, L. B. van der; Heymans, H. S. A.; Aalderen, W. M. van; Smitt, J.H. Sillevis; Knol, Jan; Amor, Kaouther Ben; Goossens, D. A.; Sprikkelman, A. B.

doi:10.1111/j.1365-2222.2010.03465.x

Cited by 127 publications

(121 citation statements)

References 53 publications

Supporting

Mentioning

109

Contrasting

Unclassified

Order By: Relevance

“…Two publications came from the same study with a later publication being a follow-up of the original trial. 274 Only the first publication, describing the original trial was included in this study.…”

Section: Resultsmentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

Programme Grants for Applied ResearchISSN 2050-4322 (Print) ISSN 2050-4330 (Online) This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).Editorial contact: nihredit@southampton.ac.ukThe full PGfAR archive is freely available to view online at www.journalslibrary.nihr.ac.uk/pgfar. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk Criteria for inclusion in the Programme Grants for Applied Research journalReports are published in Programme Grants for Applied Research (PGfAR) if (1) they have resulted from work for the PGfAR programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors. Programme Grants for Applied Research programmeThe Programme Grants for Applied Research (PGfAR) programme, part of the National Institute for Health Research (NIHR), was set up in 2006 to produce independent research findings that will have practical application for the benefit of patients and the NHS in the relatively near future. The Programme is managed by the NIHR Central Commissioning Facility (CCF) with strategic input from the Programme Director.The programme is a national response mode funding scheme that aims to provide evidence to improve health outcomes in England through promotion of health, prevention of ill health, and optimal disease management (including safety and quality), with particular emphasis on conditions causing significant disease burden.For more information about the PGfAR programme please visit the website: http://www.nihr.ac.uk/funding/programme-grants-forapplied-research.htm This reportThe research reported in this issue of the journal was funded by PGfAR as project number RP-PG-0407-10177. The contractual start date was in September 2008. The final report began editorial review in April 2014 and was accepted for publication in April 2016. As the funder, the PGfAR programme agreed the research questions and study designs in advance with the investigators. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The PGfAR editors and production house have tried to ensure the accuracy of the authors' report and would like to thank the reviewers for their constructive comments on the final report document. However, they do not accept liability for damages or losses arising from material published in this report.This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, CCF, NETSCC, PGfAR or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, ...

show abstract

Section: Resultsmentioning

confidence: 99%

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Kim

Batchelor

Bath‐Hextall

et al. 2016

Programme Grants Appl Res

View full text Add to dashboard Cite

show abstract

“…However, only three studies demonstrated statistically significant improvement in SCORAD index in the treatment group than in the control group [23,24,29]. One study found that SCORAD index was only significantly improved among patients who exhibited elevated total or specific IgE levels [25].…”

Section: Scorad Indexmentioning

confidence: 99%

Review of Pro- and/or Prebiotics in Extensively Hydrolyzed or Amino Acid-Based Infant Formula for Food Allergy

Giardina¹,

Marriage²

2017

TONUTRJ

View full text Add to dashboard Cite

show abstract

“…Два проспективных рандомизированных и плацебоконтролированных исследования у младенцев с использованием либо пребио-тических галактоолигосахаридов, либо смеси пребиотиков, не выявили снижения тяжести АД [7,105,106]. Еще в одном исследовании у детей с низким риском изучали временное профилактическое действие пробиотиков в отношении AД [7,107].…”

Section: изменения микробиоты при заболеваниях кожиunclassified

Микробиота Кожи И Возможности Ее Коррекции Пре- И Пробиотиками При Лечении Хронических Дерматозов

Litus¹,

Martyniuk²,

Bardova³

2017

Inter. jour. antoboit. and probiot.

View full text Add to dashboard Cite

В последнее время достигнут прогресс в понимании значения микробиома для здоровья человека и его роли в развитии заболеваний. Изучение изменений микробиоты кожи при хронических дерматозах помогает понять этиологию и патогенез заболеваний, что важно для разработки стратегии лечения. Перспективным направлением является применение пре- и пробиотиков для модуляции кожной микробиоты с целью улучшения состояния кожи.

show abstract

Effect of a new synbiotic mixture on atopic dermatitis in infants: a randomized‐controlled trial

Abstract: This synbiotic mixture does not have a beneficial effect on AD severity in infants, although it does successfully modulate their intestinal microbiota. Further randomized-controlled trials should explore a possible beneficial effect in IgE-associated AD.

Cited by 127 publications

References 53 publications

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

A programme of research to set priorities and reduce uncertainties for the prevention and treatment of skin disease

Review of Pro- and/or Prebiotics in Extensively Hydrolyzed or Amino Acid-Based Infant Formula for Food Allergy

Микробиота Кожи И Возможности Ее Коррекции Пре- И Пробиотиками При Лечении Хронических Дерматозов

Contact Info

Product

Resources

About